n-3 Polyunsaturated Fatty Acids in the Treatment of Pancreatic Cancer Cachexia

  • M. D. Barber
  • J. A. Ross
  • K. C. H. Fearon


Pancreatic adenocarcinoma is the fifth leading cause of cancer death in the Western world with an incidence of about 10/100 000 person-years (1). Over 95% of patients will die of their disease. The 5-year survival rate is 1.3% with a median survival of 4.1 months (2). More than 80% of cancers are irresectable at diagnosis and even in those patients suitable for surgical resection the 5-year survival rate is less than 25% in the best centres (3).


Pancreatic Cancer Polyunsaturated Fatty Acid Eicosapentaenoic Acid Acute Phase Response Advanced Pancreatic Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rosewicz S, Weidenmann B (1997) Pancreatic carcinoma. Lancet 349:485–489PubMedCrossRefGoogle Scholar
  2. 2.
    Ahlgren JD (1996) Epidemiology and risk factors in pancreatic cancer. Semin Oncol 23:241–250PubMedGoogle Scholar
  3. 3.
    Neoptolemos JP, Kerr DJ (1995) Adjuvant therapy for pancreatic cancer. Br J Surg 82:1012–1014.PubMedCrossRefGoogle Scholar
  4. 4.
    Thomas PRM (1996) Radiotherapy for carcinoma of the pancreas. Semin Oncol 23:213–219PubMedGoogle Scholar
  5. 5.
    Schnall SF, Macdonald JS. (1996) Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 23:220–228.PubMedGoogle Scholar
  6. 6.
    Casper ES, Green MR, Kelsen DP et al. (1994) Phase II trial of gemcitabine (2,2′-difluoro-deoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12:29–34.PubMedCrossRefGoogle Scholar
  7. 7.
    Rothenberg ML, Burris HA, Andersen JS et al. (1995) Gemcitabine: effective palliative therapy for pancreas cancer patients failing 5-FU. Proc Am Soc Clin Oncol 14:198Google Scholar
  8. 8.
    Moore M, Andersen J, Burris H et al. (1995) A randomised trial of gemcitabine versus 5FU as first-line therapy in advanced pancreatic cancer. Proc Am Soc Clin Oncol 14:199Google Scholar
  9. 9.
    Anonymous (1996) Biotech’s uncertain present. Lancet 347:1497CrossRefGoogle Scholar
  10. 10.
    Carmichael J, Fink U, Russell RCG et al. (1996) Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73:101–105PubMedCrossRefGoogle Scholar
  11. 11.
    Warren S (1935) The immediate causes of death in cancer. Am J Med Sci 184:610–616CrossRefGoogle Scholar
  12. 12.
    DeWys WD, Begg C, Lavin PT et al. (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 69:491–497PubMedCrossRefGoogle Scholar
  13. 13.
    Oveson L, Hannibal J, Mortensen EL (1993) The interrelationship of weight loss, dietary intake, and quality of life in ambulatory patients with cancer of the lung, breast, and ovary. Nutr Cancer 19:159–167.CrossRefGoogle Scholar
  14. 14.
    Wigmore SJ, Plester CE, Ross JA, Fearon KCH (1997) Contribution of anorexia and hypermetabolism to weight loss in anicteric patients with pancreatic cancer. Br J Surg 84:196–197.PubMedCrossRefGoogle Scholar
  15. 15.
    Fearon KCH, Carter DC (1988) Cancer cachexia. Ann Surg 208:1–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Grunfeld C, Feingold LH (1992) Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 327:329–337.PubMedCrossRefGoogle Scholar
  17. 17.
    Roubenoff R, Roubenoff RA, Ward LM, Holland SM, Hellman DB (1992) Rheumatoid cachexia: Depletion of lean body mass in rheumatoid arthritis. Possible association with tumor necrosis factor. J Rheumatol 19:1505–1510PubMedGoogle Scholar
  18. 18.
    Cangiano C, Laviano A, Muscaritoli M, Meguid MM, Cascino A, Fanelli FR (1996) Cancer anorexia: new pathogenic and therapeutic insights. Nutrition 12(Suppl) 1: S48–51.PubMedGoogle Scholar
  19. 19.
    Falconer JS, Fearon KCH, Plester CE, Ross JA, Carter DC (1994) Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 219:325–331.PubMedCrossRefGoogle Scholar
  20. 20.
    Brennan MF (1977) Uncomplicated starvation versus cancer cachexia. Cancer Res 37:2359–2364.PubMedGoogle Scholar
  21. 21.
    Chlebowski RT, Heber D, Block JB (1982) Serial assessment of glucose metabolism in patients with cancer cachexia. Clin Res 30.-69AGoogle Scholar
  22. 22.
    Edén E, Edstrom S, Bennegárd K, Scherstén T, Lundholm K (1984) Glucose flux in relation to energy expenditure in malnourished patients with and without cancer during periods of fasting and feeding. Cancer Res 44:1718–1724PubMedGoogle Scholar
  23. 23.
    Holroyde CP, Skutches CL, Boden G, Reichard GA (1984) Glucose metabolism in cachectic patients with colorectal cancer. Cancer Res 44:5910–5913PubMedGoogle Scholar
  24. 24.
    Shaw JHF, Wolfe RR (1987) Glucose and urea kinetics in patients with early and advanced gastrointestinal cancer: the response to glucose infusion, parenteral feeding, and surgical resection. Surgery 101:181–191PubMedGoogle Scholar
  25. 25.
    Jeevanandam M, Horowitz GD, Lowry SF, Brennan MF (1986) Cancer cachexia and the rate of whole body lipolysis in man. Metabolism 35:304–310PubMedCrossRefGoogle Scholar
  26. 26.
    Vlassara H, Spiegel RJ, San Doval D, Cerami A (1986) Reduced plasma lipoprotein lipase activity in patients with malignancy-associated weight loss. Horm Metabol Res 18:698–703CrossRefGoogle Scholar
  27. 27.
    Fearon KCH, Hansell DT, Preston P et al. (1988) Influence of whole body protein turnover rate on resting energy expenditure in patients with cancer. Cancer Res 48:2590–2595.PubMedGoogle Scholar
  28. 28.
    Melville S, McNurlan MA, Calder AG, Garlick PJ (1990) Increased protein turnover despite normal energy metabolism and responses to feeding in patients with lung cancer. Cancer Res 50:1125–1131PubMedGoogle Scholar
  29. 29.
    Falconer JS, Fearon KCH, Ross JA et al. (1995) Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 75:2077–2082PubMedCrossRefGoogle Scholar
  30. 30.
    Baumann H, Gauldie J (1994) The acute phase response. Immunol Today 15:74–80PubMedCrossRefGoogle Scholar
  31. 31.
    Reeds PJ, Fjeld CR, Jahoor F (1994) Do the differences between the amino acid compositions of acute-phase and muscle proteins have a bearing on nitrogen loss in traumatic states? J Nutr 124:906–910PubMedGoogle Scholar
  32. 32.
    Michie HR, Spriggs DR, Manogue KR et al. (1988) Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery 104:280–286PubMedGoogle Scholar
  33. 33.
    Starnes HF, Warren RS, Jeevanandam M et al. (1988) Tumor necrosis factor and the acute metabolic response to tissue injury in man. J Clin Invest 82:1321–1325PubMedCrossRefGoogle Scholar
  34. 34.
    Strassmann G, Fong M, Kenney JS, Jacob CO (1992) Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89:1681–1684PubMedCrossRefGoogle Scholar
  35. 35.
    Hellerstein MK, Meydani SN, Meydani M, Wu K, Dinarello CA (1989) Interleukin-1-induced anorexia in the rat. Influence of prostaglandins. J Clin Invest 84:228–235PubMedCrossRefGoogle Scholar
  36. 36.
    Espat NJ, Auffenberg T, Rosenberg J J et al. (1996) Ciliary neurotrophic factor is catabolic and shares with IL-6 the capacity to induce an acute phase response. Am J Physiol 271: R185-R190.PubMedGoogle Scholar
  37. 37.
    Aderka D, Engelmann H, Hornik V et al. (1991) Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res 51:5602–5607.PubMedGoogle Scholar
  38. 38.
    Knapp ML, Al-Sheibani S, Riches PG, Hanham IWF, Phillips RH (1991) Hormonal factors associated with weight loss in patients with advanced breast cancer. Ann Clin Biochem 28:480–486.PubMedGoogle Scholar
  39. 39.
    Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M (1993) Serum interleukin-6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin’s disease and with B symptoms. Cancer Res 53:2118–2122.PubMedGoogle Scholar
  40. 40.
    Preston T, Fearon KCH, McMillian DC et al. (1995) Effect of ibuprofen on the acute-phase response and protein metabolism in patients with cancer and weight loss. Br J Surg 82:229–234.PubMedCrossRefGoogle Scholar
  41. 41.
    Staal-van den Brekel AJ, Dentener MA, Schols AMWJ, Buurman WA, Wouters EFM (1995) Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol 13:2600–2605PubMedGoogle Scholar
  42. 42.
    Mahoney SM, Beck SA, Tisdale MJ (1988) Comparison of weight loss induced by recombinant tumour necrosis factor with that produced by a cachexia-inducing tumour. Br J Cancer 57:385–389.CrossRefGoogle Scholar
  43. 43.
    Langstein HN, Norton JA (1991) Mechanisms of cancer cachexia. Hematol Oncol Clin North Am 5:103–123PubMedGoogle Scholar
  44. 44.
    McNamara MJ, Alexander HR, Norton JA (1992) Cytokines and their role in the pathophysiology of cancer cachexia. JPEN J Parenter Enteral Nutr 16(Suppl):50S-55SPubMedCrossRefGoogle Scholar
  45. 45.
    Aderka D, Fisher S, Levo Y, Holtmann H, Hahn T, Wallach D (1985) Cachectin/tumour-necrosis-factor production by cancer patients. Lancet 11:1190.PubMedCrossRefGoogle Scholar
  46. 46.
    Heinrich PC, Castell JV, Andus T (1990) Interleukin-6 and the acute phase response. Biochem J 265:621–636PubMedGoogle Scholar
  47. 47.
    Oldenburg HSA, Rogy MA, Lazarus DD et al. (1993) Cachexia and the acute-phase protein response in inflammation are regulated by interleukin-6. Eur J Immunol 23:1889–1894PubMedCrossRefGoogle Scholar
  48. 48.
    O’Riordain MG, Ross JA, Fearon KCH (1995) Insulin and counterregulatory hormones influence acute-phase protein production in human hepatocytes. Am J Physiol 269: E323-E330PubMedGoogle Scholar
  49. 49.
    Gullo L, Ancona D, Pezzilli R, Casadei R, Campione O (1993) Glucose tolerance and insulin secretion in pancreatic cancer. Ital J Gastroenterol 25:487–489.PubMedGoogle Scholar
  50. 50.
    Schwartz SS, Zeidler A, Moosa AR, Kuku SF, Rubenstein AH (1978) A prospective study of glucose tolerance, insulin, C-peptide, and glucagon responses in patients with pancreatic carcinoma. Dig Dis 23:1107–1114CrossRefGoogle Scholar
  51. 51.
    Fox JN, Frier BM, Armitage M, Ashby JP (1985) Abnormal insulin secretion in carcinoma of the pancreas: response to glucagon stimulation. Diabetic Med 2:113–116.PubMedCrossRefGoogle Scholar
  52. 52.
    Cersosimo E, Pisters PWT, Pesola G, McDermott K, Bajorunas D, Brennan MF (1991) Insulin secretion and action in patients with pancreatic cancer. Cancer 67:486–493PubMedCrossRefGoogle Scholar
  53. 53.
    Schaur RJ, Fellier H, Gleispach H, Fink E, Kronberger L (1979) Tumor host relations. I. Increased plasma Cortisol in tumor-bearing humans compared with patients with benign surgical disease. J Cancer Res Clin Oncol 93:281–285PubMedCrossRefGoogle Scholar
  54. 54.
    Burt ME, Aoki TT, Gorschboth CM, Brennan MF (1983) Peripheral tissue metabolism in cancer-bearing man. Ann Surg 198:685–691.PubMedCrossRefGoogle Scholar
  55. 55.
    Bessey PQ, Watters JM, Aoki TT, Wilmore DW (1984) Combined hormonal infusion simulates the metabolic response to injury. Ann Surg 200:264–281PubMedCrossRefGoogle Scholar
  56. 56.
    Watters JM, Bessey PQ, Dinarello CA, Wolff SM, Wilmore DW (1986) Both inflammatory and endocrine mediators stimulate host responses to sepsis. Arch Surg 121:179–190.PubMedGoogle Scholar
  57. 57.
    Tisdale MJ (1993) Mechanism of lipid mobilisation associated with cancer cachexia: interaction between the polyunsaturated fatty acid, eicosapentaenoic acid, and inhibitory guanine nucleotide-regulatory protein. Prostaglandins Leukot Essent Fatty Acids 48:105–109.PubMedCrossRefGoogle Scholar
  58. 58.
    McDevitt TM, Todorov PT, Beck SA, Khan SH, Tisdale MJ (1995) Purification and characterisation of a lipid-mobilising factor associated with cachexia-inducing tumors in mice and humans. Cancer Res 55:1458–1463.PubMedGoogle Scholar
  59. 59.
    Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M (1996) Characterisation of a cancer cachectic factor. Nature 379:739–742.PubMedCrossRefGoogle Scholar
  60. 60.
    Grunfeld C, Zhao C, Fuller J, Pollock A, Moser A, Freidman J, Feingold KR (1996) Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. A role for leptin in the anorexia of infection. J Clin Invest 97:2152–2157PubMedCrossRefGoogle Scholar
  61. 61.
    Schwarz M (1997) Proc Nutr Soc (in press)Google Scholar
  62. 62.
    Nixon DW, Lawson DH, Kutner M et al. (1981) Hyperalimentation of the cancer patient with protein-calorie undernutrition. Cancer Res 41:2038–2045.PubMedGoogle Scholar
  63. 63.
    Cohn SH, Vartsky D, Vaswani AN et al. (1982) Changes in body composition of cancer patients following combined nutritional support. Nutr Cancer 4:107–119.PubMedCrossRefGoogle Scholar
  64. 64.
    Evans WK, Makuch R, Clamon GH et al. (1985) Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. Cancer Res 45:3347–3353.PubMedGoogle Scholar
  65. 65.
    Klein S, Simes J, Blackburn GL (1986) Total parenteral nutrition and cancer clinical trials. Cancer 58:1378–1386.PubMedCrossRefGoogle Scholar
  66. 66.
    Lipman TO (1991) Clinical trials of nutritional support in cancer. Parenteral and enteral therapy. Hematol Oncol Clin North Am 5:91–102.PubMedGoogle Scholar
  67. 67.
    Ng E-H, Lowry SF (1991) Nutritional support and cancer cachexia. Evolving concepts of mechanisms and adjunctive therapies. Hematol Oncol Clin North Am 5:161–184.PubMedGoogle Scholar
  68. 68.
    Oveson L, Allingstrup L, Hannibal J, Mortensen EL, Hansen OP (1993) Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomised study. J Clin Oncol 11:2043–2049.Google Scholar
  69. 69.
    Chlebowski RT, Bulcavage L, Grosvenor M et al. (1987) Hydrazine sulphate in cancer patients with weight loss. A placebo-controlled clinical experience. Cancer 59:406–410.PubMedCrossRefGoogle Scholar
  70. 70.
    McMillan DN, Simpson JM, Preston T et al. (1994) Effect of megestrol acetate on weight loss, body composition and blood screen of gastrointestinal cancer patients. Clin Nutr 13:85–89.PubMedCrossRefGoogle Scholar
  71. 71.
    Nelson KA, Walsh D, Sheehan FA (1994) The cancer anorexia-cachexia syndrome. J Clin Oncol 12:213–225.PubMedGoogle Scholar
  72. 72.
    Gebbia V, Testa A, Gebbia N (1996) Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer. Br J Cancer 73:1576–1580.PubMedCrossRefGoogle Scholar
  73. 73.
    Simons JPFHA, Aaronson NK, Vansteenkiste JF et al. (1996) Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: A placebo-controlled multicenter study. J Clin Oncol 14:1077–1084.PubMedGoogle Scholar
  74. 74.
    Beck SA, Tisdale MJ (1989) Effect of insulin on weight loss and tumour growth in a cachexia model. Br J Cancer 59:677–681.PubMedCrossRefGoogle Scholar
  75. 75.
    Beck SA, Tisdale MJ (1990) Effect of megestrol acetate on weight loss induced by tumour necrosis factor a and a cachexia-inducing tumour (MAC16) in NMRI mice. Br J Cancer 62:420–424.PubMedCrossRefGoogle Scholar
  76. 76.
    Leaf A, Weber PC (1988) Cardiovascular effects of n-3 fatty acids. N Engl J Med 318:549–557.PubMedCrossRefGoogle Scholar
  77. 77.
    Nordoy A, Dyerberg J (1989) n-3 fatty acids in health and disease. J Intern Med 225(Suppl 1): l–3.CrossRefGoogle Scholar
  78. 78.
    Neilsen NH, Hansen JPH (1980) Breast cancer in Greenland: selected epidemiological, clinical, and histological features. J Cancer Res Clin Oncol 98:287–299.CrossRefGoogle Scholar
  79. 79.
    Anonymous (1983) Eskimo diets and diseases. Lancet 1:1139–1141.Google Scholar
  80. 80.
    Dyerberg J, Bang HO, Hjorne N (1975) Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr 28:958–966.PubMedGoogle Scholar
  81. 81.
    Bang HO, Dyerberg J, Hjørne N (1976) The composition of food consumed by Greenland Eskimos. Acta Med Scand 200:69–73.PubMedCrossRefGoogle Scholar
  82. 82.
    Bull NL, Day MJL, Burt R, Buss DH (1983) Individual fatty acids in the British household food supply. Hum Nutr: Appl Nutr 37A:373–377.Google Scholar
  83. 83.
    Lorenz R, Weber PC, Szimnau P, Heldwein W, Strasser T, Loeschke K (1989) Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease: a randomised, placebo-controlled, double-blind, cross-over trial. J Intern Med 225(Suppl 1):225–232.Google Scholar
  84. 84.
    Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M (1996) Effect of an enteric-, coated fish-oil preparation on relapses in Crohn’s disease. N Engl J Med 334:1557–1560.PubMedCrossRefGoogle Scholar
  85. 85.
    Lau CS, Morley KD, Belch JJF (1993) Effects of fish oil supplementation on non-steroidal antiinflammatory drug requirement in patients with mild rheumatoid arthritis: a double-blind placebo controlled study. Br J Rheumatol 32:982–989.PubMedCrossRefGoogle Scholar
  86. 86.
    Arm JP, Horton CE, Eiser NM, Clark TJH, Lee TH (1988) The effects of dietary supplementation with fish oil on asthmatic responses to antigen. J Allergy Clin Immunol 81:183.CrossRefGoogle Scholar
  87. 87.
    Bjorneboe A, S0yland E, Bjorneboe G-EA, Rajka G, Drevon CA (1989) Effects of n-3 fatty acid supplement to patients with atopic dermatitis. J Intern Med 225(Suppl 1):233–236.Google Scholar
  88. 88.
    Bittiner SB, Tucker WFG, Cartwright I, Bleehen SS (1988) A double-blind randomised, placebo-controlled trial of fish oil in psoriasis. Lancet 1:378–380.PubMedCrossRefGoogle Scholar
  89. 89.
    Johnson JA, Griswold JA, Muakkassa FF (1993) Essential fatty acids influence survival in sepsis. J Trauma 35:128–131.PubMedCrossRefGoogle Scholar
  90. 90.
    Kenler AS, Swails WS, Driscoll DF et al. (1996) Early enteral feeding in postsurgical cancer patients. Fish oil structured lipid-based polymeric formula versus a standard polymeric formula. Ann Surg 223:316–333.PubMedCrossRefGoogle Scholar
  91. 91.
    van der Heide JJH, Bilo HJG, Donker JM, Wilmink JM, Tegzess AM (1993) Effect of dietary fish oil on renal function and rejection in cyclosporine-treated recipients of renal transplants. N Engl J Med 329:769–773.PubMedCrossRefGoogle Scholar
  92. 92.
    Laugharne JD, Mellor JE, Peet M (1996) Fatty acids and schizophrenia. Lipids 31 (Suppl): S163-S165PubMedCrossRefGoogle Scholar
  93. 93.
    Fischer S, Weber PC. Thromboxane A3 (TXA3) is formed in human platelets after dietary eicosapentaenoic acid (C20:5w3) (1983) Biochem Biophys Res Commun 116:1091–1099PubMedCrossRefGoogle Scholar
  94. 94.
    Lee TH, Hoover RL, Williams JD et al. (1985) Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med 312:1217–1224.PubMedCrossRefGoogle Scholar
  95. 95.
    Fitzgerald GA, Braden G, Fitzgerald DJ, Knapp HR (1989) Fish oils in cardiovascular disease. J Intern Med 225 Suppl 1:25–29.Google Scholar
  96. 96.
    Schmitt EB, Dyerberg J (1989) n-3 fatty acids and leukocytes. J Intern Med 225 (Suppl 1):151—158Google Scholar
  97. 97.
    Endres S, Ghorbani R, Kelley VE et al. (1989) The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 320:265–271.PubMedCrossRefGoogle Scholar
  98. 98.
    Meydani SN, Lichtenstein AH, Cornwall S et al. (1993) Immunological effects of National Cholesterol Education Panel Step-2 diets with and without fish-derived n-3 fatty acid enrichment. J Clin Invest 92:105–113.PubMedCrossRefGoogle Scholar
  99. 99.
    Cooper AL, Gibbons L, Horan MA, Little RA, Rothwell NJ (1993) Effect of dietary fish oil supplementation on fever and cytokine production in human volunteers. Clin Nutr 12:321–328.PubMedCrossRefGoogle Scholar
  100. 100.
    Calder PC (1996) Immunomodulatory and anti-inflammatory effects of n-3 polyunsaturated fatty acids. Proc Nutr Soc 55:737–774.PubMedCrossRefGoogle Scholar
  101. 101.
    Alam SQ, Ren Y-F, Alam BS (1988) (3H) forskolin- and (3H) dihydroalprenolol-binding sites and adenylate cyclase activity in heart of rats fed diets containing different oils. Lipids 23:207–213PubMedCrossRefGoogle Scholar
  102. 102.
    Ballou LR, Cheung WY (1985) Inhibition of human platelet phospholipase A2 activity by unsaturated fatty acids. Proc Natl Acad Sci USA 82:371–375.PubMedCrossRefGoogle Scholar
  103. 103.
    Speizer LA, Watson MJ, Brunton LL (1991) Differential effects of omega-3 fish oils on protein kinase activities in vitro. Am J Physiol 261: E109–E114.PubMedGoogle Scholar
  104. 104.
    Holian O, Nelson R (1992) Action of long-chain fatty acids on protein kinase C activity: comparison of omega-6 and omega-3 fatty acids. Anticancer Res 12:975–980.PubMedGoogle Scholar
  105. 105.
    Kang JX, Leaf A (1996) Evidence that free polyunsaturated fatty acids modify Na+ channels by directly binding to the channel proteins. Proc Natl Acad Sci USA 93:3542–3546.PubMedCrossRefGoogle Scholar
  106. 106.
    Vallette G, Vanet A, Sumida C, Nunez EA (1991) Modulatory effects of unsaturated fatty acids on the binding of glucocorticoids to rat liver glucocorticoid receptors. Endocrinology 129:1363–1369.PubMedCrossRefGoogle Scholar
  107. 107.
    Sumida C, Vallette G, Nunez EA (1993) Interaction of unsaturated fatty acids with rat liver glucocorticoid receptors: studies to localise the site of interaction. Acta Endocrinol 129:348–355.PubMedGoogle Scholar
  108. 108.
    Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W (1993) Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA 90:2160–2164.PubMedCrossRefGoogle Scholar
  109. 109.
    Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W (1996) The PPARa-leukotriene B4 pathway to inflammation control. Nature 384:39–43.PubMedCrossRefGoogle Scholar
  110. 110.
    Bégin ME, Ells G, Das UN, Horrobin DF (1986) Differential killing of human carcinoma cells supplemented with n-3 and n-6 polyunsaturated fatty acids. J Natl Cancer Inst 77:1053–1062.PubMedGoogle Scholar
  111. 111.
    Falconer JS, Ross JA, Fearon KCH, Hawkins RA, O’Riordain MG, Carter DC (1994) Effect of eicosapentaenoic acid and other fatty acids on the growth in vitro of human pancreatic cancer cell lines. Br J Cancer 69:826–832.PubMedCrossRefGoogle Scholar
  112. 112.
    McMillan DN, Murray A, Noble BS, Purasiri P, Heys SD, Eremin O (1994) Differential responses of human solid tumour cells in vitro to essential fatty acids. Eur J Surg Oncol 20:104–105.Google Scholar
  113. 113.
    Mengeaud V, Nano JL, Fournel S, Rampal P (1992) Effects of eicosapentaenoic acid, gamma-linolenic acid and prostaglandin El on three human colon carcinoma cell lines. Prostaglandins Leukot Essent Fatty Acids 47:313–319.PubMedCrossRefGoogle Scholar
  114. 114.
    Lai PBS, Ross JA, Fearon KCH, Anderson JD, Carter DC (1996) Cell cycle arrest and induction of apoptosis in pancreatic cancer cells exposed to eicosapentaenoic acid in vitro. Br J Cancer 74:1375–1383.PubMedCrossRefGoogle Scholar
  115. 115.
    Bégin ME, Ells G, Horrobin DF (1988) Polyunsaturated fatty acid-induced cytotoxicity against tumour cells and its relationship to lipid peroxidation. J Natl Cancer Inst 80:188–194.PubMedCrossRefGoogle Scholar
  116. 116.
    Karmali RA, Reichel P, Cohen LA, Terano T, Hirai A, Tamura Y, Yoshida S (1987) The effects of dietary w-3 fatty acids on the DU-145 transplantable human prostatic tumor. Anticancer Res 7:1173–1180.PubMedGoogle Scholar
  117. 117.
    Pritchard GA, Jones DL, Mansel RE (1989) Lipids in breast carcinogenesis. Br J Surg 76:1069–1073.PubMedCrossRefGoogle Scholar
  118. 118.
    Gonzalez MJ, Schemmel RA, Gray JI, Dugan L, Sheffield LG, Welsch CW (1991) Effect of dietary fat on growth of MCF-7 and MDA-MB231 human breast carcinomas in athymic nude mice: relationship between carcinoma growth and lipid peroxidation product levels. Carcinogenesis 12:1231–1235.PubMedCrossRefGoogle Scholar
  119. 119.
    Gonzalez MJ, Schemmel RA, Dugan L, Gray JI, Welsch CW (1993) Dietary fish oil inhibits human breast carcinoma growth: a function of increased lipid peroxidation. Lipids 28:827–832.PubMedCrossRefGoogle Scholar
  120. 120.
    Rose DP, Connolly JM (1993) Effects of dietary omega-3 fatty acids on human breast cancer growth and metastases in nude mice. J Natl Cancer Inst 85:1743–1747.PubMedCrossRefGoogle Scholar
  121. 121.
    Rose DP, Connolly JM, Rayburn J, Coleman M (1995) Influence of diets containing eicosapentaenoic or docosahexaenoic acid on growth and metastasis of breast cancer cells in nude mice. J Natl Cancer Inst 87:587–592.PubMedCrossRefGoogle Scholar
  122. 122.
    Hardman WE, Barnes CJ, Grant W, Knight CW, Cameron IL (1995) A high fish oil diet supplemented with ferric citrate safely inhibits primary and metastatic human breast carcinoma growth in nude mice. Proc Am Assoc Cancer Res 36:114.Google Scholar
  123. 123.
    Sakaguchi M, Imray C, Davis A et al. (1990) Effects of dietary n-3 and saturated fats on growth rates of the human colonic cancer cell lines SW-620 and LS 174T in vivo in relation to tissue and plasma lipids. Anticancer Res 10:1763–1768.PubMedGoogle Scholar
  124. 124.
    Sakaguchi M, Rowley S, Kane N et al. (1990) Reduced tumour growth of the human colonic cancer cell lines COLO-320 and HT-29 in vivo by dietary n-3 lipids. Br J Cancer 62:742–747.PubMedCrossRefGoogle Scholar
  125. 125.
    de Bravo MG, de Antueno RJ, Toledo J, De Tomás ME, Mercuri OF, Quintans C (1991) Effects of an eicosapentaenoic and docosahexaenoic acid concentrate on a human lung carcinoma grown in nude mice. Lipids 26:866–870.PubMedCrossRefGoogle Scholar
  126. 126.
    Maehle L, Eilertsen E, Mollerup S, Schønberg S, Krokan HE, Haugaen A (1995) Effects of n-3 fatty acids during neoplastic progression and comparison of in vitro and in vivo sensitivity of two human tumour cell lines. Br J Cancer 71:691–696.PubMedCrossRefGoogle Scholar
  127. 127.
    Connolly JM, Rose DP (1996) Suppression of human breast cancer metastases by dietary eicosapentaenoic acid fed as neoadjuvant therapy to nude mice. Proc Am Assoc Cancer Res 37:71.Google Scholar
  128. 128.
    Bibby MC, Double JA, Ali SA, Fearon KCH, Brennan RA, Tisdale MJ (1987) Characterisation of a transplantable adenocarcinoma of the mouse colon producing cachexia in recipient animals. J Natl Cancer Inst 78:539–546.PubMedGoogle Scholar
  129. 129.
    Tisdale MJ, Dhesi JK (1990) Inhibition of weight loss by w-3 fatty acids in an experimental cachexia model. Cancer Res 50:5022–5026.PubMedGoogle Scholar
  130. 130.
    Tisdale MJ, Beck SA (1991) Inhibition of tumour-induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid. Biochem Pharmacol 41:103–107.PubMedCrossRefGoogle Scholar
  131. 131.
    Beck SA, Smith KL, Tisdale MJ (1991) Anticachectic and antitumour effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res 51:6089–6093.PubMedGoogle Scholar
  132. 132.
    Hudson EA, Beck SA, Tisdale MJ (1993) Kinetics of the inhibition of tumour growth in mice by eicosapentaenoic acid-reversal by linoleic acid. Biochem Pharmachol 45:2189–2194.CrossRefGoogle Scholar
  133. 133.
    Hudson EA, Tisdale MJ (1994) Comparison of the effectiveness of eicosapentaenoic acid administered as either the free acid or ethyl ester as an anticachectic and antitumour agent. Prostaglandins Leukot Essent Fatty Acids 51:141–145.PubMedCrossRefGoogle Scholar
  134. 134.
    Ohira T, Nishio K, Ohe Y et al. (1996) Improvement by eicosanoids in cancer cachexia induced by LLC-IL6 transplantation. Cancer Res Clin Oncol 122:711–715.CrossRefGoogle Scholar
  135. 135.
    Takahashi M, Przetakiewicz M, Ong A, Borek C, Lowenstein JM (1992) Effect of co3 and co6 fatty acids on transformation of cultured cells by irradiation and transfection. Cancer Res 52:154–162.PubMedGoogle Scholar
  136. 136.
    Abou-El-Ela SH, Prasse KW, Carroll R, Wade AE, Dharwadkar S, Bunce OR (1988) Eicosanoid synthesis in 7,12-dimethylbenz(a)anthracene-induced mammary carcinomas in Sprague-Dawley rats fed primrose oil, menhaden oil or corn oil diet. Lipids 23:948–954.PubMedCrossRefGoogle Scholar
  137. 137.
    Reddy BS, Sugie S (1988) Effect of different levels of omega-3 and omega-6 fatty acids on azoxymethane-induced colon carcinogenesis in F344 rats. Cancer Res 48:6642–6647.PubMedGoogle Scholar
  138. 138.
    Karmali RA, Chao C-C, Basu A, Modak M (1989) II. Effect of n-3 and n-6 fatty acids on mammary H-ras expression and PGE2 levels in DMBA-treated rats. Anticancer Res 9:1169–1174.PubMedGoogle Scholar
  139. 139.
    Kaizer L, Boyd NF, Kriukov V, Trichler D (1989) Fish consumption and breast cancer risk: An ecological study. Nutr Cancer 12:61–68.PubMedCrossRefGoogle Scholar
  140. 140.
    Sasaki S, Horacsek M, Kesteloot H (1993) An ecological study of the relationship between dietary fat intake and breast cancer mortality. Prev Med 22:187–202.PubMedCrossRefGoogle Scholar
  141. 141.
    Caygill CPJ, Charlett A, Hill MJ (1996) Fat, fish, fish oil and cancer. Br J Cancer 74:159–164.PubMedCrossRefGoogle Scholar
  142. 142.
    Sardesai VM (1992) The essential fatty acids. Nutr Clin Pract 7:179–186.PubMedCrossRefGoogle Scholar
  143. 143.
    von Schacky C, Weber PC (1985) Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J Clin Invest 76:2446–2450.CrossRefGoogle Scholar
  144. 144.
    Holroyde CP, Skutches CL, Reichard GA (1988) Effects of dietary enrichment with n-3 polyunsaturated fatty acids in metastatic breast cancer. Proc Am Soc Clin Oncol 7:42.Google Scholar
  145. 145.
    Anti M, Armeiao F, Marra G et al. (1994) Effects of different doses of fish oil on rectal cell proliferation in patients with sporadic colonic adenomas. Gastroenterol 107:1709–1718.Google Scholar
  146. 146.
    Wigmore SJ, Ross JA, Falconer JS et al. (1996) The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 12(Suppl): S27–S30.PubMedGoogle Scholar
  147. 147.
    Wigmore SJ, Ross JA, Barber MD, Fearon KCH (1997) Phase II trial of high purity eicosapentaenoic acid in patients with pancreatic cancer cachexia. Proc Nutr Soc (in press)Google Scholar
  148. 148.
    Wigmore SJ, Fearon KCH, Ross JA, Carter DC (1996) Eicosapentaenoic acid, cytokines and the acute-phase protein response in pancreatic cancer. Br J Surg 83:1649–1650.Google Scholar
  149. 149.
    Wigmore SJ, Fearon KCH, Maingay JP, Ross JA (1997) Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sei 92:215–221.Google Scholar

Copyright information

© Springer-Verlag London Limited 1999

Authors and Affiliations

  • M. D. Barber
  • J. A. Ross
  • K. C. H. Fearon

There are no affiliations available

Personalised recommendations